 Home > Medical News > Medicines Company News > 2022 ESMO:DZD1516 International Multicenter Breast Cancer Clinical Study Results Positive

2022 ESMO:DZD1516 International Multicenter Breast Cancer Clinical Study Results Positive

 Last Update: 2022-09-14
 Source: Internet
 Author: User

Tags

benazepril 20 mg

chemotherapy drugs

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The 2022 Annual Meeting of the European Society of Oncology (ESMO) published safety and pharmacokinetic data

Research Tips:

DZD1516 has good safety, tolerability, pharmacokinetic properties, excellent blood-brain barrier penetration, and shows initial antitumor activity

Twice-daily (BID) of 250 mg was determined to be MTD, and doses of 250 mg BID and below were not reported for dose-limit toxicity (DLT) and adverse events associated with inhibition of wild-type EGFR

In patients, the Kpuu, CSF (ratio of cerebrospinal fluid to free drug concentrations in plasma) of DZD1516 was 2.

Eighteen patients completed tumor evaluation after at least one dose, and among patients who had previously received median 7-line antineoplastic therapy (86% had received HER2 TKI treatment), the best antineoplastic efficacy of DZD1516 monotherapy intracranial, intracranial, and overall was disease-stable

*As of February 20, 2022

Patients with advanced HER2-positive breast cancer have up to 60% of brain metastases and have a very poor

Dr.

The 2022 Annual Meeting of the European Society of Oncology (ESMO) published safety and pharmacokinetic data

Research Tips:

DZD1516 has good safety, tolerability, pharmacokinetic properties, excellent blood-brain barrier penetration, and shows initial antitumor activity

Twice-daily (BID) of 250 mg was determined to be MTD, and doses of 250 mg BID and below were not reported for dose-limit toxicity (DLT) and adverse events associated with inhibition of wild-type EGFR

In patients, the Kpuu, CSF (ratio of cerebrospinal fluid to free drug concentrations in plasma) of DZD1516 was 2.

*As of February 20, 2022

Patients with advanced HER2-positive breast cancer have up to 60% of brain metastases and have a very poor

Dr.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.